NLRP3 and metabolic dysfunction-associated steatohepatitis: Additionally, Liraglutide has shown promise in human and experimental studies for the prevention of NASH by inhibiting NLRP3 inflammasome activation and pyroptosis in PA + LPS-treated hepatocytes.